Document Detail

The multifunctional deoxynucleoside kinase of insect cells is a target for the development of new insecticides.
MedLine Citation:
PMID:  10727530     Owner:  NLM     Status:  MEDLINE    
The antiherpetic agent (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was found to be an efficient substrate for recombinant Drosophila melanogaster-deoxyribonucleoside kinase with a K(m) of 4.5 microM and a V(max) of 400 nmol/microg protein/h compared with 1.3 microM and 62.5 nmol/microg protein/h, respectively, for the natural substrate thymidine. Mammalian cytosolic thymidine kinase-1 does not recognize BVDU as a substrate. In sharp contrast to mammalian cells, the insect D. melanogaster and Spodoptera frugiperda (Sf) embryonic cells proved highly sensitive to the cytostatic action of BVDU. BVDU was efficiently metabolized to its 5'-mono-, 5'-di- and 5'-triphosphate derivatives in the insect cell cultures and abundantly incorporated into the insect cell DNA. BVDU prevented the D. melanogaster cells to initiate the S phase of their cell cycle, and exposure of S. frugiperda cells to BVDU led to a dose-dependent retardation of the insect cells in the S phase of their cell cycle. Both inhibition of nucleic acid synthesis (through the 5'-triphosphate of BVDU) and inhibition of thymidylate synthase (through the 5'-monophosphate of BVDU) would account for the cytostatic activity of BVDU against the insect cells. Because of the virtual lack of cytotoxicity of BVDU against mammalian cells, the drug should be considered highly selective in its cytostatic action against the insect cells. When added to the food of S. frugiperda larvae, BVDU caused a remarkable decrease in the weight gain of the larvae and heavily compromised the transformation of the larvae to the pupae and their subsequent adult (moth) phase. Our data indicate that insect multifunctional deoxyribonucleoside kinase should be considered an entirely novel and attractive target in the development of new nucleoside types of highly selective insecticidal drugs.
J Balzarini; B Degrève; S Hatse; E De Clercq; M Breuer; M Johansson; R Huybrechts; A Karlsson
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Molecular pharmacology     Volume:  57     ISSN:  0026-895X     ISO Abbreviation:  Mol. Pharmacol.     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-05-04     Completed Date:  2000-05-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0035623     Medline TA:  Mol Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  811-9     Citation Subset:  IM    
Rega Institute for Medical Research, Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bromodeoxyuridine / analogs & derivatives,  metabolism,  pharmacology
Cell Cycle / drug effects
Cell Division / drug effects
Deoxycytidine / metabolism
Drosophila melanogaster / cytology,  enzymology*
Insecticides / metabolism,  pharmacology*
Mitochondria / drug effects,  enzymology
Phosphotransferases (Alcohol Group Acceptor) / drug effects*,  metabolism
Thymidine / pharmacology
Thymidine Kinase / drug effects,  metabolism
Thymidylate Synthase / metabolism
Reg. No./Substance:
0/Insecticides; 10028-17-8/Tritium; 50-89-5/Thymidine; 59-14-3/Bromodeoxyuridine; 91593-18-9/3',5'-di-O-acetyl-5-(2-bromovinyl)-2'-deoxyuridine; 951-77-9/Deoxycytidine; EC Synthase; EC 2.7.1.-/Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.-/deoxyribonucleoside kinases; EC 2.7.1.-/thymidine kinase 2; EC Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl...
Next Document:  Alterations in detergent solubility of heterotrimeric G proteins after chronic activation of G(i/o)-...